drugset / Trial / NCT05037435

Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.

NCT05037435 ↗

Phase 3 Completed 40 enrolled Limited Liability Company Pharm Aid
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of the presented study was to evaluate the safety and immunological efficacy in preventing the rotavirus infection within a cohort of healthy subjects (target age of 18-45 years old) by using the pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried).

Timeline

Start
2018-06-25
Primary completion
2018-07-27
Completion
2018-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Rota-V-Aid™ Vaccine 2.5 ml Oral

Indications